Table 1 Summary of studies included in the present meta-analysis
Study | Subjects, n | Age, yr | HPV vaccine (Type of HPV) | Control | Country/Region | Follow-up, months | Reporting of adverse events | Outcome | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
2vHPV | 4vHPV | 9vHPV | Primary | Secondary | |||||||
027 Study [26] | 841 | 22.8 ± 2.1 | ✓ | placebo | Japan | 30 | Self-reported | ✓ | |||
028 Study [26] | 107 | 12.7 ± 2.4 | ✓ | placebo | Japan | 30 | Self-reported | ✓ | |||
Bhatla 2010 [27] | 354 | 28.4 ± 4.91 | ✓ | placebo | India | 7 | Self-reported | ✓ | ✓ | ||
Draper 2013 [28] | 198 | 12 (median) | ✓ | 4vHPV | United Kingdom | Not mention (at least 7 days) | Self-reported | ✓ | |||
Einstein 2009 [29] | 1106 | 30.5 | ✓ | 4vHPV | United States | 7 | Self-reported | ✓ | |||
FUTURE II 2007 [30] | 12,167 | 20.0 ± 2.2 (HPV) 19.9 ± 2.1 (Control) | ✓ | placebo | Multinational | 36 | Self-reported | ✓ | ✓ | ||
Harper 2004 [31] | 1113 | 20 ± 3 | ✓ | placebo | Multinational | 27 | Self-reported | ✓ | ✓ | ||
Kang 2008 [32] | 176 | 16.6 | ✓ | placebo | Korea | 7 | Self-reported | ✓ | ✓ | ||
Kim 2011 [33] | 225 | 22 ± 2.37 | ✓ | placebo | Korea | Not mention (at least 30 days) | Self-reported | ✓ | ✓ | ||
Kim 2010 [34] | 321 | 11.9 ± 1.41 | ✓ | hepatitis A vaccine | Korea | 7 | Self-reported | ✓ | ✓ | ||
Konno 2009 [35] | 1022 | 22.5 ± 1.7 | ✓ | hepatitis A vaccinea | Japan | 7 | Self-reported | ✓ | |||
Lim 2014 [36] | 271 | 24.9 ± 4.02 | ✓ | placebo | Malesia | Not mention (at least 30 days) | Self-reported | ✓ | |||
Medina 2010 [37] | 2067 | 12.1 ± 1.4 | ✓ | hepatitis A vaccine | Multinational | 12 | Self-reported | ✓ | ✓ | ||
Mugo 2015 [38] | 250 | - | ✓ | placebo | Africa | 7 | Self-reported | ✓ | ✓ | ||
Munoz 2009 [39] | 3819 | 34.3 ± 6.3 | ✓ | placebo | Multinational | Not mention (at least 15 days) | Self-reported | ✓ | |||
Ngan 2010 [40] | 300 | 26 ± 4 | ✓ | placebo | Hong-Kong | 7 | Self-reported | ✓ | |||
Paavonen 2007 [41] | 18,644 | 20.0 ± 3.1 | ✓ | hepatitis A vaccine | Multinational | 12 | Self-reported | ✓ | ✓ | ||
Perez 2008 [42] | 6004 | 19.8 ± 3.0 (HPV) 20.3 ± 2.2 (Control) | ✓ | placebo | Multinational | 7 | Self-reported | ✓ | |||
Skinner 2014 [43] | 5752 | 37.0 ± 7.2 (HPV) 37.0 ± 7.3 (Control) | ✓ | placebo | Multinational | 48 | Self-reported | ✓ | |||
Sow 2013 [44] | 676 | 16.9 ± 4.29 | ✓ | placebo | Africa | 12 | Reported by trained field worker | ✓ | |||
Vesikari 2015 [45] | 600 | 12.6 ± 1.9 | ✓ | 4vHPV | Europe | 7 | Self-reported | ✓ | ✓ | ||
Villa 2006 [46] | 1106 | 20.0 ± 1.7 | ✓ | placebo | Multinational | 7 | Self-reported | ✓ | ✓ | ||
Zhu-1 2014 [47] | 750 | 13.1 ± 2.43 | ✓ | placebo | China | 12 | Self-reported | ✓ | ✓ | ||
Zhu-2 2014 [47] | 1212 | 35.7 ± 4.99 | ✓ | hepatitis B vaccine | China | 12 | Self-reported | ✓ | ✓ | ||